Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.53 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.53 |
| ▸ | ACVR1 | Q04771 | 11/20 | 0.48 |
| ▸ | FLT3 | P36888 | 4/20 | 0.47 |
| ▸ | NEK2 | P51955 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3183888 | 0.84 | KDR (0.51) | KDRFGFR3ACVR1FLT3NEK2 | |
| SCHEMBL29845362 | 0.83 | NEK2 (0.61) | ACVR1NEK2FYN | |
| SCHEMBL27040051 | 0.80 | KMT2A (0.53) | FYN | |
| SCHEMBL17556159 | 0.77 | ACVR1 (0.69) | KDRACVR1FLT3 | |
| SCHEMBL17556202 | 0.76 | ACVR1 (0.70) | KDRACVR1FLT3FYN | |
| SCHEMBL17556225 | 0.76 | ACVR1 (0.68) | KDRACVR1FLT3NEK2FYN | |
| SCHEMBL17556214 | 0.75 | KDR (0.82) | KDRFGFR3FLT3 | |
| SCHEMBL3382949 | 0.74 | FLT3 (0.58) | KDRFGFR3FLT3 | |
| SCHEMBL3198958 | 0.74 | KDR (0.70) | KDRFGFR3ACVR1 | |
| SCHEMBL3186080 | 0.74 | KDR (0.74) | KDRFGFR3FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904494-B1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | LILLY CO ELI (US) | 2010-12-01 | — | — | EP | disclosed |
| US-7666879-B2 | Imidazo[1,2-A]pyridine compounds as VEGF-R2 inhibitors | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090227622-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY | 2009-09-10 | — | — | US | disclosed |
| EP-1904494-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2006091671-A1 | IMIDAZO (1, 2-A) PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227622-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | KDR, FLT1, FLT4 | KDR 1/4885FGFR3 60/4885ACVR1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.